PHAT (Phathom Pharmaceuticals) Marketable Securities: $0.0 Mil (As of Mar. 2026)


PHAT Phathom Pharmaceuticals Inc PHAT
23 GF Score
Price $12.61
! 3 Warning Signs
View Full Analysis

What is Phathom Pharmaceuticals Marketable Securities?

Phathom Pharmaceuticals PHAT +3.70% 23 Marketable Securities is $0.0 Mil as of Mar. 2026. GuruFocus rates PHAT with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Phathom Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $0.0 Mil.

Phathom Pharmaceuticals  (NAS:PHAT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Phathom Pharmaceuticals Marketable Securities Related Terms

Phathom Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Phathom Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phathom Pharmaceuticals Marketable Securities Chart

Phathom Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Phathom Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PHAT
23GF Score
Phathom Pharmaceuticals Inc PHAT
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phathom Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.0 Mil mean?
Phathom Pharmaceuticals (PHAT) has a Marketable Securities of $0.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Phathom Pharmaceuticals and its competitors.
Is Phathom Pharmaceuticals' Marketable Securities too high?
Phathom Pharmaceuticals' current Marketable Securities is $0.0 Mil. Overall, Phathom Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' Marketable Securities compare to GERN and ODTX?
Phathom Pharmaceuticals' Marketable Securities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current Marketable Securities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Phathom Pharmaceuticals (PHAT) has a current Marketable Securities of $0.0 Mil. The current Marketable Securities is $0.0 Mil. Phathom Pharmaceuticals' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current Marketable Securities is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Phathom Pharmaceuticals Business Description

Address 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
23GF Score

Get the complete analysis for PHAT

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.61
Price